Merit Medical Systems (MMSI) to Release Earnings on Wednesday

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Wednesday, July 30th. Analysts expect Merit Medical Systems to post earnings of $0.85 per share and revenue of $372.47 million for the quarter.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.11. The firm had revenue of $355.35 million for the quarter, compared to analysts' expectations of $352.57 million. Merit Medical Systems had a net margin of 8.81% and a return on equity of 15.52%. The firm's revenue was up 9.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.77 EPS. On average, analysts expect Merit Medical Systems to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Merit Medical Systems Trading Up 0.6%

NASDAQ:MMSI traded up $0.47 on Friday, reaching $84.69. The stock had a trading volume of 537,957 shares, compared to its average volume of 719,060. The company has a market cap of $5.01 billion, a price-to-earnings ratio of 41.51, a P/E/G ratio of 2.72 and a beta of 0.65. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.87 and a quick ratio of 3.26. The firm's fifty day moving average is $92.67 and its two-hundred day moving average is $97.65. Merit Medical Systems has a 12-month low of $82.62 and a 12-month high of $111.45.

Insider Buying and Selling

In other Merit Medical Systems news, CEO Fred P. Lampropoulos sold 400 shares of the stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $95.61, for a total value of $38,244.00. Following the completion of the sale, the chief executive officer owned 1,045,628 shares of the company's stock, valued at $99,972,493.08. This trade represents a 0.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Raul Jr. Parra sold 15,181 shares of the stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $93.75, for a total transaction of $1,423,218.75. Following the completion of the sale, the chief financial officer directly owned 24,201 shares of the company's stock, valued at $2,268,843.75. This trade represents a 38.55% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 85,596 shares of company stock valued at $8,171,433 over the last three months. Company insiders own 3.20% of the company's stock.

Hedge Funds Weigh In On Merit Medical Systems

A hedge fund recently raised its stake in Merit Medical Systems stock. AQR Capital Management LLC grew its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 7.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,361 shares of the medical instruments supplier's stock after acquiring an additional 1,114 shares during the quarter. AQR Capital Management LLC's holdings in Merit Medical Systems were worth $1,730,000 as of its most recent filing with the SEC. 99.66% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on MMSI shares. Piper Sandler restated an "overweight" rating and issued a $110.00 target price (up from $106.00) on shares of Merit Medical Systems in a report on Friday, May 23rd. JPMorgan Chase & Co. began coverage on shares of Merit Medical Systems in a report on Friday, March 28th. They issued an "overweight" rating and a $120.00 target price on the stock. Robert W. Baird cut their price objective on shares of Merit Medical Systems from $111.00 to $110.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Canaccord Genuity Group set a $112.00 price objective on shares of Merit Medical Systems and gave the stock a "buy" rating in a report on Wednesday, May 21st. Finally, Needham & Company LLC reiterated a "buy" rating and set a $108.00 price objective on shares of Merit Medical Systems in a report on Friday, July 18th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $109.11.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.